Shangbay Capital
VC Fund
Palo Alto, United States
Shangbay Capital is a VC fund in Palo Alto focused on Health Care and Medical Device. Best-in-class investments mainly in the U.S. medical devices technology, as well as biotech, and mobile healthcare sectors through early sta
- Total investments:
- 50
- Last investment:
- Lead investor:
- 26%
- Fund size:
- $48M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Shangbay Capital invests in
Stages Shangbay Capital invests in
Countries Shangbay Capital invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
3 more contacts available
Round size
- Series A
- $5.1M–$25M
- Series B
- $10M–$123M
Investment Focus
Industry
- Health Care 30 (60%)
- Medical Device 20 (40%)
- Medical 16 (32%)
- Biotechnology 14 (28%)
- Therapeutics 5 (10%)
Stage
- Series A 17 (34%)
- Series B 10 (20%)
- Funding Round 4 (8%)
- Series C 3 (6%)
- Series D 3 (6%)
Country
- United States 33 (66%)
- China 1 (2%)
- Canada 1 (2%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Erik Engelson
Venture Partner
|
Venture Partner | Total investments: 1 | Find email | |
William Dai
Founding Managing Partner
|
Founding Managing Partner | Total investments: 18 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Sound Health
|
Sound Health uses acoustic resonance to provide nasal relief. Its current product is an app that scans the face to map the bone structure and then a headband that plays music at personalized frequencies for 10 minutes. The headband is off the shelf and the sound levels are akin to wearing earpods. It envisions the headband to be over-the-counter(OTC) so it’s easily accessible to patients, whether prescribed by doctors or not. | $12.3M / Series A / Jul 30, 2026 | |
Sound Health & Wellness Center
|
Sound Health & Wellness Center offers health benefits via a Taft-Hartley trust, including virtual care and case management. | $12.3M / Series A / Jul 28, 2026 | |
Nervonik
|
Nervonik is a medical device company developing an opioid-free peripheral nerve stimulation (PNS) system. Nervonik is focused on advancing clinical research and achieving regulatory milestones to bring its innovative therapies to market. | $52.5M / Series B / Apr 27, 2026 | |
Petal Surgical
|
Petal Surgical is a healthcare platform that intends to make surgery accessible and incisionless. | $10M / Series A / Oct 20, 2025 | |
SetPoint Medical
|
SetPoint Medical is a company that developed a device-based therapeutic approach for treating rheumatoid arthritis. The company's product, the SetPoint System, is a small, wireless implantable device that stimulates the vagus nerve to reduce inflammation. The therapy is an approach for adults with active rheumatoid arthritis who have notresponded to other treatments. | $115M / Series D / Aug 11, 2025 | |
Evident Vascular
|
Evident Vascular offers an advanced IVUS platform that leverages Artificial Intelligence to deliver superior Vascular. | Series B / Mar 25, 2025 | |
Fluid Biomed
|
Fluid Biotech is a Calgary based company that aims to develop the next generation of stents to improve patient well-being and realise better health and quality of life through innovation. | $27M / Series A / Dec 16, 2024 | |
Inquis Medical
|
Inquis Medical is developing thrombectomy technology, enabling an efficient single-pass thrombectomy with minimal blood loss. | $40M / Series B / Nov 04, 2024 | |
Venova Medical
|
Venova Medical develops vascular access systems for patients requiring renal replacement therapy. It addresses patient level and system barriers for access creation while simultaneously providing quickly functioning access with less need for intervention. The company was founded in 2018 and is headquartered in Los Gatos, California. | $30M / Series B / Sep 04, 2024 | |
Avation Medical
|
Avation Medical is pioneering new platforms for wearable nerve stimulation systems. They believe empowering patients to be in control of their therapies will allow for more personalized and custom care. That's why at Avation Medical, they are re‑imagining neuromodulation by developing patient‑centric solutions based on powerful, proven, smarttechnologies.Avation Medical transforms the neuromodulation market to elevate care for patients with chronic conditions. | $22M / Series C / Feb 01, 2024 | |
| See all 50 investments → | |||
Co-Investors
Action Potential Venture Capital
6 deals together
Catalio Capital Management
5 deals together
Morgenthaler Ventures
5 deals together
Richard King Mellon Foundation
5 deals together
Gilmartin Capital LLC
4 deals together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Featured in Investor Lists
Recommended lists
FAQ
What does Shangbay Capital invest in?
Shangbay Capital invests primarily in Health Care, Medical Device and Medical startups, most often at Series A and Series B stage. Most of the 50 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Shangbay Capital's check size?
Shangbay Capital typically joins rounds of $5.1M–$25M at Series A and $10M–$123M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Shangbay Capital participates in.
How do I contact Shangbay Capital?
Public channels for Shangbay Capital include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Shangbay Capital?
The team at Shangbay Capital includes Erik Engelson (Venture Partner) and William Dai (Founding Managing Partner). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
